Bioanalytical Systems, Inc. (BASI) rated Buy with price target $3.75 by Ladenburg Thalmann
Bioanalytical Systems, Inc. (NASDAQ: BASI)
rated Buy with price target $3.75 by Ladenburg Thalmann.
Bioanalytical Systems, Inc.
is a contract research organization providing research and development resources to many of the leading pharmaceutical, medical device and biotechnology companies in the world. The company offers an efficient, variable-cost alternative to its clients' internal product development, compliance and quality control programs. The company provides a broad array of value-added services and products focused on chemical analysis, allowing its clients to perform their research and development functions either ``in-house`` or at the company.
Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann
provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann
’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.